Late-breaking abstract: Is primary tumour standardized uptake value (SUV) an independent prognostic factor for non small cell lung cancer (NSCLC)? A meta-analysis based on individual data
M. Paesmans, C. Y. O. Wong, E. F. Patz, R. Komaki, S. Eschmann, R. Govindan, J. Vansteenkiste, A. P. Meert, W. de Jong, K. Higashi, G. Borst, A. Van Baardwijk, L. Ameye, J. J. Lafitte, T. Berghmans, C. Garcia, P. Flamen, R. Rami Porta, J. P. Sculier (Brussels, Leuven, Belgium; Royal Oak, Durham, Houston, St-Louis, United States Of America; Tubingen, Germany; Groningen, Amsterdam, Maastricht, Netherlands; Ishikawa, Japan; Lille, France; Barcelona, Spain)
Source: Annual Congress 2011 - Imaging, functional evaluation and staging for lung cancer patients
Disease area: Thoracic oncology
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
M. Paesmans, C. Y. O. Wong, E. F. Patz, R. Komaki, S. Eschmann, R. Govindan, J. Vansteenkiste, A. P. Meert, W. de Jong, K. Higashi, G. Borst, A. Van Baardwijk, L. Ameye, J. J. Lafitte, T. Berghmans, C. Garcia, P. Flamen, R. Rami Porta, J. P. Sculier (Brussels, Leuven, Belgium; Royal Oak, Durham, Houston, St-Louis, United States Of America; Tubingen, Germany; Groningen, Amsterdam, Maastricht, Netherlands; Ishikawa, Japan; Lille, France; Barcelona, Spain). Late-breaking abstract: Is primary tumour standardized uptake value (SUV) an independent prognostic factor for non small cell lung cancer (NSCLC)? A meta-analysis based on individual data. Eur Respir J 2011; 38: Suppl. 55, 2750
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Primary tumour standardised uptake value is prognostic in nonsmall cell lung cancer: a multivariate pooled analysis of individual data Source: Eur Respir J 2015; 46: 1751-1761 Year: 2015
Validation and comparison of several published prognostic systems for patients with small cell lung cancer Source: Eur Respir J 2011; 38: 657-663 Year: 2011
Biological factors predicting response to chemotherapy (CT) in advanced non small cell lung cancer (NSCLC): A feasibility study on the collection of tissue Source: Annual Congress 2010 - The role of biomarkers in lung cancer Year: 2010
The prognostic value of the albumin-to-fibrinogen ratio in lung cancer patients. Source: International Congress 2019 – Biology and prognosis of lung cancer Year: 2019
Prognostic value of mean platelet volume in non-small cell lung cancer: a real-world, registry-based study Source: International Congress 2019 – Early detection, follow-up and epidemiology of lung cancer Year: 2019
Espression of vascular endothelial growth factor (VEGF) and its receptors (VEGF-R1-Flt1, VEGF-R2-Flk1) in non small cell (NSCLC) and small cell lung carcinomas (SCLC). Correlation with clinical outcome Source: Annual Congress 2008 - Biology in thoracic tumours Year: 2008
Validation of the prognostic value of growth pattern classification in operated non-small cell lung cancer (NSCLC) Source: Annual Congress 2010 - Actual challenges in thoracic surgery Year: 2010
COX-2 as prognostic factor in lung cancer: systematic review of the literature with meta-analysis Source: Annual Congress 2005 - Prognostic factors in lung cancer Year: 2005
Small cell lung cancer: prognostic significance and correlation with clinical and laboratory parameters Source: Eur Respir J 2007; 30: Suppl. 51, 670s Year: 2007
The effect on disease free survival of different regimens of chemotherapy (CT) in non small cell lung cancer (NSCLC) Source: Eur Respir J 2004; 24: Suppl. 48, 672s Year: 2004
C-kit (CD 117): a new prognostic factor in small cell lung cancer (SCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 478s Year: 2001
Analysis of clinical factors in relationship to treatment effects of erlotinib in non small cell lung cancer (NSCLC) patients Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008
Characteristics and prognostic relevance of p 53 gene mutations in Polish non small cell lung cancer (NSCLC) patients Source: Eur Respir J 2005; 26: Suppl. 49, 92s Year: 2005
HER2/Neu overexpression as independent negative prognostic factor for non-small cell lung cancer Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010
Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis Source: Eur Respir J 2001; 18: 705-719 Year: 2001
The role of angiogenesis, assessed by microvessel count (MVC), on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis Source: Eur Respir J 2002; 20: Suppl. 38, 3s Year: 2002
Overall survival analysis and characterization of an EGFR mutated non small cell lung cancer (NSCLC) population Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up Year: 2017
Survival outcomes of non small cell lung cancer (NSCLC) patients who are suitable for radical treatment at initial presentation Source: Annual Congress 2011 - Quality management for lung cancer patients Year: 2011
Is it possible to predict response to cancer chemotherapy (CTh) in patients (pts) with non-small cell lung cancer (NSCLC) on the basis of serum CYFRA 21-1 level (sCY21)? Source: Eur Respir J 2002; 20: Suppl. 38, 74s Year: 2002
Prognostic value of apoptotic index (AI) considered jointly with cell cycle regulators in non-small cell lung cancer (NSCLC) Source: Eur Respir J 2006; 28: Suppl. 50, 387s Year: 2006